Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's First Quarter 2021 Financial Results Conference Call. At this time, all participants are in listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, today's call is being recorded.
It is now my pleasure to turn the floor over to Billy Cho, Chief Financial Officer of Zai Lab, who will make introductions, introductory comments.
Good morning, and welcome to Zai Lab's Q1 2021 financial results and corporate updates conference call. Earlier this morning, DIALab issued a press release providing the details of the company's financial results for the 3 months ended March 31, 2020 as well as product highlights and corporate updates. The press release is available in the Investor Relations section of the company's corporate website at ir.dialaboratory.com. Today's call will be led by Doctor. Samantha Du, DIALab's Founder, Chairperson and Chief Executive Officer.
She will be joined by Tao Fu, Chief Strategy Officer, who will provide more details on our recent commercial and pipeline progress Jonathan Wong, Head of Business Development Doctor. Alan Sandler, President, Head of Global Development, Oncology and Doctor. Harold Reinhart, Chief Medical Officer for Autoimmune and Infectious Diseases will also be available to answer questions during the Q and A portion of the call. As a reminder, during today's call, Zai Lab will be making certain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our business plans and objectives and timing and success for our clinical trials, regulatory applications and commercial launches. Such forward looking statements are not guarantees of future performance and therefore, you should not put undue reliance upon them.
These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. I refer you to our SEC filings for a discussion of risk factors that could cause our actual results to differ materially from those discussed today. At this time, it is my pleasure to turn the call over to Zai Lab's Founder, Chairperson and Chief Executive Officer, Doctor. Samantha Du.
Thank you, Billy. Hello, everyone, and thank you all for joining us. On this call, I'll discuss some of the highlights from the Q1 and provide remarks as to why we believe Zai Lab's future has never been greater. We are off to a great start this year and believe 2021 will be another strong year of execution, the quality and speed that Skylight has been known to deliver. Therefore, to become a leading global pharmaceutical company by executing our growth strategy.
Since Bud Light was founded in 2014, we have quickly expanded to create a portfolio of 21 innovative products across more than 40 applications. We have now commercialized the 4th 2 of this product in China with 4 indications. In March 2021, we gained approval for KEYLUX as a 3rd oncology product approved within the last 15 months in China. Innovation has recently received encouraging news on several of our key assets from our customers. CLA filing of exogartigumab and GMG was accepted by the FDA for the PDUFA date of December 17, 2021.
The Phase 3 pivotal renal trial of chemo treating cells in non small cell lung cancer was recommended to continue the reduced sample size based on an accelerated interim analysis. In bema, with granted breakthrough therapy designation by the FDA, a good line treatment for gastric cancer patients who overextrate FcSR2b. We now have a total of 17 products in clinical development, of which 11 are in late stage development, and 5 have already been approved in the U. S. In short, we have a broad innovative portfolio with a visible pathway to achieve significant scale within just a few years.
I also want to highlight that along with our growing pipeline of utilizing products, we have 7 early stage programs with worldwide, including 3 in global clinical trials. In the Q1, satellite continued to execute well with no large size of our business. We entered into several strategic collaborations to further strengthen our gastric and long term strategic strongholds. The music company hosted our OCV franchise with an exclusive agreement with argenx for Efgartipinox, a true pipeline of product opportunity. Advanced numerous clinical programs towards key data readouts.
Bringing regulatory approval for Kinlox, our first commercial product, in what we expect to become the leading gastric cancer franchise. We generated strong revenue growth. Zejula was added to NRG well in December of last year. We expect to see continued strong volume growth of Zejula and remain confident in our ability to be the market share leader in China, with this important divestment clause in ovarian cancer. With the closing of our recent global topics offering, its growth proceeds for nearly 800,000,000, dollars We significantly strengthened our capital position.
With new capital, they allow us to expand our pipeline through additional strategic partnerships, accelerate the clinical development of our product portfolio, scaled R and D in commercial organization to drive strong revenue growth and enhance our global platform. We remain on target to advance all aspects of our platform throughout 2021. We continue to expect MMP approval of Nuvera for community acquired bacterial pneumonia, and acute bacterial skin and skin structure infections. We plan to file MARTICIMAT for HER2 positive breast cancer, TPCs for mesothelioma and Zejula for mainline ovarian countries in China. We're actively engaging with NMPA on a regulatory filing strategy for escharitumab in TDMT, and we anticipate numerous data readouts, including both KEYWOG treatment field for liver cancer and ovarian cancer, the KEYWOG, the 2nd largest 2 for margetizumab, the gastric cancer for CLN-eighty one, the non small cell lung cancer and for PPS-seventy two in non small cell lung cancer and gastric cancer.
We are now in mission to address serious unmet medical needs for patients in China and around the world, we continue to execute on another aggressive growth strategy. It creates substantial value. As demonstrated by our progress in the 1st quarter, we remain focused as ever on achieving our mission, and our future has never been greater. With that, I'll now ask Paul to discuss our performance and prospect in more detail. Carl?
Thank you, Samantha. I will comment on the performance of our ongoing launches and discuss recent product highlights. First, I'd like to touch on Zejula. As a reminder, Zejula is approved in China for 1st and second line ovarian cancer and is the only PARP inhibitor approved for all comers in first line. In comparison, Lynparza has a label restricting its use to patients with Gbloc communication, which comprise only about 15% of overall patients in this study.
No other PARP inhibitors have been approved for either 1st or second line. The results of the PRIMA study conducted by GSK globally and of the NORA study sponsored by Zai in China demonstrated that an individualized starting dose regimen of Vedula preserved efficacy while improving the product side effect profile. This further differentiates Vedula from other PARP inhibitors. This quarter we achieved an important milestone. Our team was successful in gaining inclusion on a national reimbursement drug list for second line ovarian cancer within the same year of our launch.
This further underscores Tejula's significant clinical value for a broad range of ovarian cancer patients. The rapid NRDL inclusion provides patients much greater access and we're already starting to see strong volume growth. In addition, our team has also been successful gaining coverage for commercial health insurance with coverage currently being provided by 67 commercial health insurance plans and 52 supplemental insurance plans. We're very pleased with our launch performance so far and over time we believe the doula will become the leading PARP inhibitor in China. Moving to Optune, as you recall, we launched Optune in China in the second half of twenty twenty.
The product is the 1st novel treatment in GBM approved by the NMPA in the last 15 years. It was highly anticipated by the medical community and it was already recommended by the China's National Glioma Guideline prior to launch. With our team's effort, Optune became the 1st innovative medical device supported by commercial health insurance in China and is also covered in 13 supplemental insurance plans. We deployed innovative strategies to support patient access and rapid uptake, including establishing 28 direct to patient centers in China. Importantly, we're working with our partner Novocure to potentially expand the indications of tumor treating field in areas of large unmet medical needs.
Additional late stage studies are underway in tumor types potentially affecting over 1,500,000 new patients a year in China, including in non small cell lung cancer where that has been an important development. Last month, our partner NovaCure announced an update regarding the global Phase 3 pivotal LUNAR trial. After the review by an independent data monitoring committee or DMC, NovoCure was informed by the committee that the pre specified interim analysis for the LUNAR trial has been accelerated given the length of accrual and a number of events observed. The DMC further concluded that it is likely unnecessary and possible unethical for patients randomized to the control arm to continue accrual to 534 patients with 18 month follow-up. The DMC recommended a reduced sample size of approximately 276 patients with a 12 month follow-up, which could potentially accelerate the overall timeline of the trial by more than a year.
NovoTure has filed an IDE supplement with the FDA and is awaiting the agency's response. We're encouraged by this important update in lung cancer, an area of huge unmet medical need in China. I look forward to additional clinical data readouts from Novocure in pancreatic, liver and ovarian cancers, in brain pathophysies and in glioblastoma with high intensity arrays. We also have a China only Phase 2 pilot trial in gastric cancer that is expected to complete enrollment this year. And we continue to be on target to file tumor treating fields in mesothelioma later this year.
Now I'd like to discuss the recent regulatory approval for Ching Loc. We filed Ching Loc for approval in China last July. It was accepted under priority review and NDA was approved in March, one full quarter ahead of the original schedule. We expect to launch the product in 4th line GIST in the Q2. Chinnlock is the 1st approved tyrosine kinase inhibitor designed specifically for just patients regardless of mutational status.
The Invictus trial demonstrated a significant benefit versus placebo in progression free survival and overall survival and served as a basis of the chin lock approvals in both U. S. And China. Top line data for the Phase 3 global pivotal INTRIG trial in second line JIT are expected in the second half of twenty twenty one and could potentially support label expansion in this important indication. We have many other products we'd like to discuss with you, but in the interest of time, I will highlight 1, bimelecizumab.
This compound is a 1st in class antibody that is being developed in gastric and gastroesophageal junction cancer as a targeted therapy for tumors that overexpress FGFR2b. In data presented at APPRO GI in January, bema in combination with modified FOLFOX demonstrated statistically significant improvement versus placebo versus modified FOLFOX in all three efficacy endpoints of the FIGHT trial, including progression free survival and overall survival. Bema could address a significant unmet need in China. There are 680,000 new cases of gastric cancer every year, approximately 87% to 88% of which are HER2 negative and about 30% of these are potential patients for bema. The compound was a key driver in Amgen's $1,900,000,000 acquisition of in April, when bema also received breakthrough designation from the FDA.
Amgen is actively planning for pivotal Phase 3 study and is considering studying the compound in additional indications such as greater cell non small cell lung cancer. We will work closely with our new partners to maximize the full potential for this exciting product. I would like to say a few words about our business development execution last quarter and beyond. We entered into 3 highlights strategic collaboration recently with Argenx, Turning Point and Coliman Oncology in Greater China. FCAR TIGIMOG became the anchor asset for our autoimmune franchise with true pipeline in the product potential.
Since we entered into the partnership, FCAR's ELA for gMG was accepted with a PDUFA date of December 17, 2021. Phase 3 trials are ongoing in CIDP, PENSAGIS and ITP and Zai Lab plans to enroll Chinese patients to these trials. Argenx also plans to identify and begin clinical testing in 2 additional indications this year with more being planned for future years. CLN-eighty one and TPX-twenty two significantly bolstered our lung cancer and gastric cancer franchises, two areas where we have built world class portfolios. These deals are great examples of how we use business development as a key strategy to quickly expand our business vertically and horizontally and create a sustainable platform to buy land.
Going forward, with our strong track record of execution and the new capital we raised through recent equity offering, we will continue to leverage our positive 2A status to strengthen our pipeline through BD efforts. Our BD pipeline remains very strong. Looking ahead into remainder of 2021, Zai Lab alongside our development and commercial partners is once again positioned to achieve key milestones, which are summarized in our press release. We plan to expand indications on commercial products, achieve approvals for new products, submit for new regulatory approvals, provide key clinical data readouts from both late and early stage programs, initiate numerous pivotal studies across our pipeline, advance internally developed assets with global rights and aggressively pursue new business development opportunities. The goals without saying, we're committed to continuing by its track record of efficient and effective execution.
Now, I would like to turn the floor over to my colleague, Billy Cho, Chief Financial Officer to discuss our recent financing and our Q1 of 2021 financial results.
Thank you, Tal. I will give a brief summary of our recent financing and review of our financial results for the Q1 of 2021. Last month, we closed on a global offering of both American depository shares and ordinary shares with gross proceeds to DIALab of approximately $857,500,000 This offering was the first ever dual tranche offering in both NASDAQ and the Hong Kong Stock Exchange. As mentioned before, this new strategic capital will allow us to expand our pipeline through collaboration agreements, accelerate the clinical development of our product portfolio and scale the R and D and commercial organizations to drive strong revenue growth and enhance our global pipeline for years to come. Moving to our financial results for the 3 months ended March 31, 2021, net product revenues were $20,100,000 compared to $8,200,000 for the same period in 2020.
Revenues for the period were comprised of $4,600,000 for Zejula compared to $6,300,000 for the same period in 2020 and $7,100,000 for Optune compared to $1,900,000 for the same period in 2020. Research and development expenses were $203,900,000 for the 3 months ended March 31, 2021 compared to $33,700,000 for the same period in 2020. The increase in R and D expenses was primarily attributable to the $52,300,000 upfront payment in Zai Lab Equity, which was determined at the fair value of the shares on the closing date given certain restrictions and the $75,000,000 development cost sharing payment to argenx as well as the $25,000,000 upfront to Turning Point. There were also additional expenses related to ongoing and newly initiated late stage clinical trials and payroll and payroll related expenses from increased R and D headcount. Selling, general and administrative expenses were $35,800,000 for the 3 months ended March 31, 20 21, compared to $18,700,000 for the same period in 2020.
The increase was primarily due to payroll and payroll related expenses from increased commercial headcount and related costs as Zai Lab continued to expand its commercial operations in China. For the 3 months ended March 31, 2021, Zai Lab reported a net loss of $232,900,000 or a loss per share attributable to common stockholders of $2.64 compared to a net loss of $48,000,000 or a loss per share attributable to common stockholders of $0.66 for the same period in 2020. As previously highlighted, the increase in net loss was primarily attributable to the new collaboration agreements with argenx and Turning Point recorded in R and D expenses. As of March 31, 2021, cash and cash equivalents, short term investments and restricted cash totaled $1,014,000,000 compared to $1,188,000,000 as of December 31, 2020. In addition, in April 2021, Zai Lab announced the closing of a global follow on offering.
The expected total proceeds to Zai Lab, including both the American depository shares offering and the ordinary shares offering, net of underwriting fees and other operating expenses, are approximately $818,100,000 We would now like to turn the call back over to the operator to open the line for questions. Operator?
Thank you. We'd like to open the line for questions. The first question comes from the line of Yigal Nochomovitz from Citigroup. Your line is open. Please go ahead.
Hi, good morning. Hi, Samantha, Billy and Tao, thank you very much for taking the question. Thao, you mentioned that the BB pipeline remains very strong. So what should we expect in terms of the pace of new business development initiatives over the near term? And is the plan to continue to expand in disease areas where you already have exposure such as oncology, autoimmune and infectious disease?
Or would you consider branching out perhaps into new areas such as rare disease and into additional treatment modalities, for example, cell therapy, where you currently don't have exposure?
Thank you, Yigal. And Johnson, do you want to address that question?
Sure. Thanks for the question, Yigal. So I think over the last few years, we have really established very sustainable platform as a company. And I think really to our development and commercialization regulatory teams combined efforts. We've built up scale.
We've built up leadership in China and demonstrated through track record. And as a result of that, these days, as Tal mentioned, we're getting a lot of inbound interest from potential partners as well as from existing partners across very diverse areas and products. For us, always, we aspire to bring in global quality, best in class, 1st in class assets. The quality is always the most important. And I think if you look at our track record over the last couple of years, I think our track record speaks to itself.
And I think as we continue to build, our BD strategy is always to support the company's growth. And our ambition is ultimately to be a global biopharmaceutical company. And so your question also asked about therapeutic areas. I think if you look at especially for example last 12 months, we've done a number of deals which actually expanded our therapeutic areas. For example, the Regeneron deal as well as the Argenx deal and we got into 2 areas in dermatology as well as the autoimmune diseases, which we did not have strong presence in beforehand.
And very quickly through these anchor assets, we're able to build a pretty nice pipeline in those new areas. So going forward, I think we definitely continue to strengthen existing disease strongholds in oncology, for example, in lung and gas and in areas like these, it's been very important for us, but also potentially to get into new therapeutic areas like what we've done with argenx, with Regeneron, and potentially also to enter into collaborations that would further accelerate our global ambition. So hopefully that answers your question, Yigal.
Yes. Thank you very much.
Thank you. Our next question is from the line of Timo Fernandez of Guggenheim. Your line is open. Please go ahead.
Targeted therapy. Just hoping you could help us understand, amongst the U. S. Companies, there are some concerns raised about the pace of targeted therapy and patient identification in the market today. I was hoping to just understand better, given your broad targeted therapy portfolio, how this might differ in China?
Or if you just think that the market is misinterpreting, the pace of uptake relative to the U. S. Market and some other developed markets of these targeted therapies that you have partnered relative to COVID. So I'm just trying to maybe ask if you guys can tease out a little bit more of the strategy and optionality with the broad targeted portfolio. And if you see that having significant advantages in China or if you just think that the concerns that are being raised today by investors around the pace of targeted therapy update and patient identification, if that's really more of a COVID related issue in your view?
Thanks so much.
Thank you, Ximena. We we have cardiac therapies, we have immunotherapy, we also have a tumor treating fit and O3 offers a functional process for combo activity. Specifically to target therapies, we have, for example, even in lung cancer and gastric cancers, we have several targeted therapies addressing different patient populations. And I don't think COVID has much impact to our business from last year and this year, pretty much based on where you can see from our revenue and from other clinical development perspective. And also, I think China is right now more and more close to the developed countries treatment of treatment standards and the diagnostic companion diagnostic companies are also going very well.
Together with these global diagnostic companies, they don't see much issues with patient documentation or funding the right patient population. Having said so, if you look at our pipeline, the current 3 approved products, they are all o commerce status. For example, the Zuzuera is the only first line o commerce among the therapies for ovarian cancer patients. In second line in the first line and second line, and so while Kinlox also is the only all comers status for later line patient population. And also for Optune, there's also the there's no diagnostic requirement.
So for us, right now, we are in a very good position to able to have a broader coverage to the patient population, which each one of them has a much greater patient population than in the other countries. Jim, did I answer your question?
Yes. I mean, that makes sense. I guess as you move forward and it was more a question of, are there opportunities to kind of utilize your broader portfolio to optimize patient identification for the targeted therapies. I know that that's something that's unique to Zai Lab relative to others. But that
I think you answered my question. Thanks, Vanessa.
Thank you. Yes, again, say, we brought a very good point because in each one disease cohort, we have multiple and target therapies. So when we go to a doctor, we can offer many different test partners with different options for treatment based on the mutation type. Thank you.
Thank you. Our next question is from the line of Hsu Yi Chen of Goldman Sachs. Your line is open. Please go ahead.
Thank you and congratulations on the strong quarter and thanks for taking my questions. With the recent public offering, I think Zai Lab now have a very strong cash position about like RMB 1,800,000,000. So it will be great that management could share with us more colors on how you're going to spend that money. What would that be? Are you going to accelerate the pace for the BDDOs?
Or you're going to spend more efforts on the in house discovery team build up? Or any color on building out the significant bigger commercial team? So trying to understand how you're going to allocate the resources and beef up the in house pipeline and also the commercial strength. Thank you.
Yes. That's a very good question, Xu Min. Good evening. I'll ask Billy to address the question.
Sure, D. Thanks for the question. So you're right, right now, if you add in the capital raise during April, we do have a little over $1,800,000,000 in cash if you combine that with the March close balance. But specifically through the capital raising from last month, it is based on our fundamental strategic needs. So to your question, the answer is yes in terms of the strategic capital, prior to accelerate the timeline to scale the China further.
And breaking down further into specific areas within the functional departments, a good part of it will go to fund new business opportunities in terms of BD, corporate development licensing opportunities, as we were talking about in the call as well as the earnings release itself. And then also, we've identified opportunities to complete additional clinical trials, advance each of our candidates and just overall scale up our R and D platform. And the same goes to our commercial effort. We have a very significant schedule of not only ramping up the 3 innovative products we have right now, but we have many more Q4 potential approval and launch over the next few years, as you know, even like over 10 with just the current pipeline in the medium term. So making sure that we can absorb that type of growth is going to be important.
So we want to allocate some funding to expand our commercialization efforts. And then last but not least, also to enhance our global pipeline. So these are the 4 broad areas where we see we're going to deploy this capital and create additional shareholders value.
Got it. Thank you, Billy.
Thank you. Next question is from the line of Anupam Rama of JVM. Please go ahead. Your line is open.
Open.
Maybe I can ask
a quick one on Kinloch here. I know it's early days and the GIST launch is expected later this month. But just wondering how we should be thinking about that launch curve here, say, relative to Zejula? Thanks so much.
Good morning, Adam. Thank you for your questions. Billy, do you want to address that?
Yes, sure. Abhutans, thanks for the question. You're right. It's pretty exciting times right now. We're going to have our 1st launch in gastric cancer franchise with Kinlox in advance.
Just we expect to launch this month in May. And we think that
we have an opportunity here to establish a
new standard of care for treating patients with Advant GIST in China. And of course, later this year, we also have TECLION data coming out. So we're anticipating that outcome as well. So we'll see. So as you know, at a pump, there's approximately 30,000 GIST patients newly diagnosed in China every year.
So it's quite a significant number, quite as many as U. S. And Europe combined. So we have significant opportunity. And we have already built a commercial team in our gastric cancer franchise to launch Ken Rockwell, and we're ready to go.
So we're not giving guidance just yet, but it's pretty exciting.
Thanks for taking our questions.
Thank you. Next question is from the line of Jonathan Chang of SVB Leerink. Please go ahead. Your line is open.
Hi, guys. Congrats on the progress and thanks for taking my question. With the recent approvals of anti PD-one drugs in frontline gastric cancer, can you talk about how this impacts your gastric cancer strategy with multiple partner programs in the
space? Good morning, Jonathan. Thank you for the question. Allen, do you want to address the question?
Sure. Thank you very much and thanks for the question. Of course, as you know, gastric cancer is the 2nd largest cancer in China, both in terms of incidence and mortality and our significant unmet needs. Fortunately, more and more treatment options are available. We've talked about mentioned FEMEA earlier.
And the FTF 2R expression appears to be orthogonal in that it appears to occur in those patients, not necessarily expressing HER2, for example. So there continues to be a definite admin need and opportunity there as well. With respect to HER2 and the recent accelerated approval for pemetrexed, we still believe as does our partners, MacroGenics, that there is definitely an opportunity there and continue to evaluate margetuximab with the QV-one checkpoint case and believe that this may create synergistic anti tumor activity to enhance tumor specific T cell immunity. So we still believe there are considerable opportunities in this important area. Have I addressed your question?
Yes, partially. Maybe I can just sneak in a follow-up then on bemirtuzumab specifically. How should we be thinking about next regulatory and development steps? What could a potential Phase III study look like in the context of evolving gastric cancer
landscape? Jonathan, go ahead, Ali.
I think that we are I think it's safe to say we're working with our partner, Amgen, in evaluating the recent changes that have occurred in this particular area and we'll be working towards the optimal design of that Phase 3 study moving forward.
Got it. Thank you.
Thank you.
Thank you. Next question is from the line of Michael Yee of Jefferies. Please go ahead. Your line is open.
Hi, thank you. Congrats on a great quarter of progress. Going back to the follow-up about the recent significant capital raise, I was wondering about your consistent stated goal to become a global pharmaceutical company. I'm wondering if that specifically means that you would be interested in expanding more so into other geographies, Asia, East or West, and thinking about what that means to become a global pharmaceutical company beyond China and how the capital raise may play a role in that, if at all? Thank you so much.
Good morning, Michael. Thank you. This is early morning for you, right? In the West Coast. Thank you for your question.
And I think as we mentioned earlier, we're definitely aspire to be a global pharma company. And in the next critical years, we plan to have additional 10 lakh products launched without taking into account any new partnerships, indication expansions or combo studies. What I also like to highlight is China is now the 2nd largest global market. And going forward, it's going to continually double digit growth. So doing well in China, we're doing well globally.
And we also, as I mentioned earlier, we have a very strong pipeline. On top of what we talked about, we have 3 products already approved with 1 more to be approved this year and 10 more to be approved over the next 3 to 4 years. We believe our commercial position is very strong in Greater China and Asia. However, we also have a very strong pipeline, not only at later stage, but early stage with we talked about 7 internal discovered pipeline with global rights, including 3 in global Phase 1 trials. We do believe by the next 3 to 4 years, we will have some of them entering into pivotal stage.
And of course, innovation, we have a very strong 3G team and other DBT continue to seek strategic collaboration to bring more promising assets that address and that kind of excludes our portfolio. Some can be of global rights, some can be of China rights based on the stage and also based on the patient population. And this is also along our strategy to supplement our own internal pipeline. Accordingly, and we have over the last few years expanding on the other footprint and other R and D team globally. We have now teams not only in China, in Shanghai, in Beijing in R and D, but also we have teams in Boston and San Francisco focusing R and D as well.
And I would believe that all of these approaches, we are well positioned to realize our ambition in the near future. Thank you.
Thank you.
Thank you. We have Yan Huang of Credit Suisse for the next question. Your line is
open.
Thank you for management to take my questions. So my question is on Tumor Treating Fields commercialization progress in China. So we understand it's already almost a year since we commercially launched the product in China. Can you give us kind of more color on commercial progress? For example, if compared to developed countries, I mean, to China patients, they own a device longer or shorter?
We have various collaboration with supplemental insurance in China. And how does those insurance plan increase our new patients who are using our devices? And yes, any color on commercialization would be helpful. Thank you.
Sure, sure. Good evening. I'd like Billy to address your question.
Hey, Yang. Thanks for the question. So the sales of Optune in China has been robust. So you saw from our earnings release that Q1 2021 came in at RMB 7,100,000 dollars compared to $1,900,000 in the same period last year. And the momentum is quite strong as we continue on in Q2 and beyond.
So we're not yet giving full year guidance, but I'll just also let you know that given the momentum, we did double the number of sales teams from about 50 at launch to about 100 now. And to your point also, you specifically mentioned other pair types that we've been able to leverage and to set up some of your adoption. And you're exactly right. So there are 13 supplemental insurance plans that we were added to and there's additional commercial plans as well. It's mostly still driven by private pay, but we think that over the longer term, these additional pair of pools, if you will, is going to be quite favorable long term and the contribution should increase.
So those are all trending in the right direction. So hopefully and oh yes, you also asked about sort of the experience we've had specifically with Chinese patients and how they compare to sort of ex China patients. So we're not giving specifics on that, partly because the launch is relatively new as well. It's really kind of in the back half of second half, late kind of back half of second half last year, where Optune kind of was kind of we were actually kind of in the initial stages of the current launch curves. But we see strong uptick, as I previously mentioned before, new patients and we're collecting good data right now on a monthly basis and it's definitely trending on the right path and we think that we're going to set a new benchmark in terms of 1st 12 months scripts.
Okay. Thanks a lot.
Thank you. We have David Ng from Macquarie for the next question. Please go ahead. Your line is open.
Hi, it's David Ng from Macquarie. Thank you for taking my question. If I may, I can just focus on the JUUL and Optune again. So for Q1, very strong year over year sales. Can you tell a little bit about the quarter over quarter trend for the Jeweller?
And then I guess specifically after March, when the new price and NLDL coverage kicks in, can you share with us what you noticed on the ground, especially in terms of volume expansion? Is the speed satisfactory and entering into April May, has the ramp up continued? So that's the JUULA. And again, maybe also comparing against the 2 new competitors. Of course, their indication are not the same as you guys.
But I noticed that their price is also quite comparable with, I guess, Beijing also just recently launched there. So any thoughts along that line in terms of further pricing strategy for the rest of this year? So even post NLDL inclusion, any thinking of offering some more kind of PAP program on top of NLDL to be competitive on Zejula? So sorry, a couple of questions on Zejula. On Optune, basically, I guess, a strategic question in the next 3 to 4 years.
With much fewer competitive threat in China, does it make sense not to go after NLDL like on a national level? And if that's the case, does it mean that it can afford your team more time to ramp it up more gradually and then achieve maybe potentially even higher peak sales rather than compared to some of the other innovative drugs in China where they have to really go intensive in the 1st 2 years after NLDL inclusion? So that's kind of my question on the 2 products. Thank you.
Yes. Good evening, David. And I think you asked a lot of questions. For the interest of time, I would like Billy to take some items from your questions to address. Billy?
Yes, sure. Thanks, Vanessa. Thanks, Tegha, for the question. So let me go through 1 by 1. But I'll go backwards and then address the earlier one.
So in terms of Optune and your questions about sort of optimizing the private pay channel with a comprehensive strategy, the short answer is yes. So we've always said that for Optune, for GBM, that's going to be the base strategy and that there are other indications, larger indications that are progressing quite well, especially with weakened use. So we'll kind of revise our strategy once those get finalized and ultimately approved and launched. So fingers crossed and that's going to be a great position to be. Can we what can we do above and beyond sort of the current comprehensive private pay strategy with not only out of pocket, but it's following plans, commercial payers, open insurance, etcetera.
Because David, to your point, clearly, that approach, if you do it well, achieves irrational pricing as well as increase adoption. So to layer on something about that, we think will be a positive, but to be continued. To your first group of questions on Zejula, I believe you were talking about sort of the competitive landscape and then our Q1 ramp. So in terms of the competitive landscape, you're right. I think the best way that we're the way we'll characterize it is we part after class is becoming quite important to address not only the ovarian cancer patients, but even beyond that in China.
And that's great to see the awareness building up in this asset class because we believe that we have already positioned Tejula as a best in class PARP inhibitor. And we see that in our although we're not giving guidance and specific kind of KPIs, but we already see that. And in Q3, when the NRDL was implemented, we saw a clear kind of volume ramp up. And of course, it's going to continue in terms of kind of adopting and sort of absorbing and transitioning to an NRDL drug, right, because you have to now go out and get on all the hospital listings. But of course, the number of hospital listings has kind of noted upwards, trending up nicely into the Q2 and beyond.
And of course, that's the reason why we've also doubled the number of sales came from 150 at launch to 300 as of right now, and we'll continue to invest because we see good momentum. And yes, so hopefully those hopefully, I did an excellent job in answering your questions.
Thank you.
Yes. I think, David, regarding to competitive landscape for Zuzuwa, we right now are the only 10 cities who has all mono all commerce status approved. Any ocommerce status approved was very impressive. And we also, on the second line, got into NRDL end of last year. So the 2 competitors you mentioned, we don't view them as our competitors because they are in breakout and the later lines and they have just launched this year.
Thank you. So we don't see a way to address we don't at least for multiple near term, we see any justification for us to modify our strategy because of those later comments for later line patients.
Thank you.
Further questions at this time. I will now turn the call back over to Zynad's CEO, Samantha Du for closing remarks.
Thank you, operator. I want to thank everyone for taking the time to join us on the call today. We appreciate our support and look forward to updating you periodically on our progress throughout the year. Operator, you may now disconnect this call. Thank you all.
Thank you. And this concludes today's conference call and thank you for participating. You may now disconnect.